Combating the West Nile virus through immunology
A European project to develop a recombinant vaccine and therapeutic antibodies against the West Nile virus infection
A significant challenge
Although 80% of the WNV cases are asymptomatic, 1% of the infections lead to serious problems affecting the central nervous system that can cause death, especially in immunosuppressed individuals and in people over 60.
Our Methods
At LWNVIVAT, we are utilizing computational tools to develop a recombinant vaccine and therapeutic antibodies targeting the West Nile virus, triggering an immune response that covers all variants. We will assess the efficacy of the developed antigens using in vitro, ex vivo and in vivo models.
Better health for everyone
With the vaccine candidate and the therapeutic antibodies developed in our project, we aim to reduce morbidity and mortality associated with the WNV infection. If the vaccine is successful, it could lead to the development of other effective vaccines against similar viruses.